Benzinga's options scanner has just identified more than 8 option transactions on Regeneron Pharmaceuticals REGN, with a cumulative value of $289,480. Concurrently, our algorithms picked up 4 puts, worth a total of 195,130.
Predicted Price Range
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $600.0 and $940.0 for Regeneron Pharmaceuticals, spanning the last three months.
Volume & Open Interest Development
In today's trading context, the average open interest for options of Regeneron Pharmaceuticals stands at 74.33, with a total volume reaching 62.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Regeneron Pharmaceuticals, situated within the strike price corridor from $600.0 to $940.0, throughout the last 30 days.
Regeneron Pharmaceuticals 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| REGN | PUT | TRADE | BULLISH | 01/16/26 | $820.00 | $80.4K | 50 | 0 |
| REGN | PUT | TRADE | BULLISH | 01/17/25 | $940.00 | $48.3K | 46 | 0 |
| REGN | PUT | SWEEP | BULLISH | 01/19/24 | $830.00 | $36.5K | 43 | 0 |
| REGN | CALL | TRADE | BULLISH | 01/19/24 | $865.00 | $34.0K | 50 | 20 |
| REGN | CALL | TRADE | BULLISH | 12/22/23 | $835.00 | $32.3K | 82 | 25 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Current Position of Regeneron Pharmaceuticals
- Trading volume stands at 379,702, with REGN's price up by 0.02%, positioned at $842.02.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 42 days.
What Analysts Are Saying About Regeneron Pharmaceuticals
In the last month, 5 experts released ratings on this stock with an average target price of $1014.4.
- An analyst from Truist Securities has revised its rating downward to Buy, adjusting the price target to $1045.
- An analyst from Truist Securities downgraded its action to Buy with a price target of $1045.
- Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Regeneron Pharmaceuticals, targeting a price of $937.
- In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $1045.
- An analyst from TD Cowen persists with their Outperform rating on Regeneron Pharmaceuticals, maintaining a target price of $1000.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
